Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Citric Acid, Iron(2+) Salt
2. Fe(ii) Citrate
3. Fenelmin
4. Fenilene
5. Feredaim
6. Ferromia
7. Ferrostec
8. Ferrous Citrate
9. Ferrous Citrate Fe 58
10. Ferrous Citrate Fe 59
11. Ferrous Citrate Fe-58
12. Ferrous Citrate Fe-59
13. Ferrous-58 Citrate
14. Ferrous-59 Citrate
15. Ferrutope
16. Iromia
17. Monoferrous Acid Citrate
18. Sodium Ferrous Citrate
19. Tetrasodium Ferrous Dicitrate
1. 23383-11-1
| Molecular Weight | 545.73 g/mol |
|---|---|
| Molecular Formula | C12H10Fe3O14 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 4 |
| Exact Mass | 545.811862 g/mol |
| Monoisotopic Mass | 545.811862 g/mol |
| Topological Polar Surface Area | 281 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 211 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 5 |
Hematinic
O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ: Merck and Co., Inc., 2001., p. 716
The in vitro and in vivo availability of iron from total parenteral nutrition solutions to which ferrous citrate has been added was investigated. In vitro experiments showed that 74% of the added iron was available to transferrin. In 7 patients in whom in vivo availability was tested by red cell incorporation, the mean availability was 81%. It was concluded that ferrous citrate is a safe and effective means of iron supplementation in patients on TPN therapy.
Sayers MH et al. JPEN J Parenter Enteral Nutr 7 (2): 117-20 (1983)
Trace Elements
A group of chemical elements that are needed in minute quantities for the proper growth, development, and physiology of an organism. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) (See all compounds classified as Trace Elements.)
Gastrointestinal absorption of iron is adequate ... /yet/ ... lower from ferrous citrate ... /than ferrous sulfate, fumarate, gluconate, succinate, glutamate, and lactate/.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1315
This study demonstrated that anticholinergic agents decreased iron absorption in man and animals. Six normal males were given 10 Ci of 59Fe ferrous citrate dissolved in water containing 250 mg of ferrous sulfate after an overnight fast. Whole body counts were done 4 hours later and used as baseline studies. Sixty minutes before the administration of radioiron, the subjects received a dose of 62.5 mg of hexocyclium methosulfate (Tral). The dose was repeated 6 hours later. Four hours after ingestion of radioiron, whole body counting was done. Every 5 days thereafter, for 15 days, a plateau of body radioactivity was reached in all subjects. Percentage absorption was calculated from the final to initial counts, after correction. Similar experiments were done in rats with atropine sulfate. In both experiments, the anticholinergic agent produced a decrease in iron absorption. The effect of atropine persisted when the iron was delivered intragastrically, but not intraduodenally. Another set of experiments showed that iron absorption decreases when radioiron is intraduodenally given in deproteinized acid gastric juice, or in 0.1N HCl, but not when mixed with neutralized gastric juice.
Orrego-Matte H et al; Am J Dige Dis 16 (9): 789-795 (1971)
The uptake of ferrous citrate 59Fe was studied in pregnant rats with or without a 4-dimethylamino-stilben(DS)-induced sarcoma tumor. ... The embryo showed higher concentrations of 59Fe. ... Iron loading only affected the embryo liver. Tumors and the placenta showed a different incorporation of 59Fe.
PMID:3857177 Anghileri LJ et al; Eur J Nucl Med 10 (5-6): 288-9 (1985)
ABOUT THIS PAGE
A Monoferrous Acid Citrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Monoferrous Acid Citrate, including repackagers and relabelers. The FDA regulates Monoferrous Acid Citrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Monoferrous Acid Citrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Monoferrous Acid Citrate supplier is an individual or a company that provides Monoferrous Acid Citrate active pharmaceutical ingredient (API) or Monoferrous Acid Citrate finished formulations upon request. The Monoferrous Acid Citrate suppliers may include Monoferrous Acid Citrate API manufacturers, exporters, distributors and traders.
click here to find a list of Monoferrous Acid Citrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Monoferrous Acid Citrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Monoferrous Acid Citrate active pharmaceutical ingredient (API) in detail. Different forms of Monoferrous Acid Citrate DMFs exist exist since differing nations have different regulations, such as Monoferrous Acid Citrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Monoferrous Acid Citrate DMF submitted to regulatory agencies in the US is known as a USDMF. Monoferrous Acid Citrate USDMF includes data on Monoferrous Acid Citrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Monoferrous Acid Citrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Monoferrous Acid Citrate suppliers with USDMF on PharmaCompass.
Monoferrous Acid Citrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Monoferrous Acid Citrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Monoferrous Acid Citrate GMP manufacturer or Monoferrous Acid Citrate GMP API supplier for your needs.
A Monoferrous Acid Citrate CoA (Certificate of Analysis) is a formal document that attests to Monoferrous Acid Citrate's compliance with Monoferrous Acid Citrate specifications and serves as a tool for batch-level quality control.
Monoferrous Acid Citrate CoA mostly includes findings from lab analyses of a specific batch. For each Monoferrous Acid Citrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Monoferrous Acid Citrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Monoferrous Acid Citrate EP), Monoferrous Acid Citrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Monoferrous Acid Citrate USP).
LOOKING FOR A SUPPLIER?
